In mice that are given a high-fat diet, an increased production of the enzyme DPP4* by the liver promotes an increase in body fat, the development of fatty liver disease and insulin resistance. These were the findings of a current study by DZD-researchers in Potsdam and Tübingen. "In combination with our observations from additional human and cell studies, these results indicate that increased DPP4 production by the liver is the cause rather than the consequence of a fatty liver and insulin resistance," says the head of the study, Annette Schürmann from the German Institute for Human Nutrition Research (DIfE), a partner of the German Center for Diabetes Research (DZD). The research team led by Schürmann has now published its findings in Molecular Metabolism.
"DPP4 inhibitors** are well known from the treatment of diabetes. Therefore, in our opinion, they could be used in the future not only to improve the sugar metabolism but also to treat non-alcoholic fatty liver disease***," adds the lead author of the study, Christian Baumeier from DIfE.
DPP4 is an enzyme that, to a large extent, is produced by the liver and inhibits the effects of important intestinal hormones that are involved in blood glucose metabolism. In addition, patients suffering from non-alcoholic fatty liver disease have elevated DPP4 levels in their blood. To date, however, it was unclear whether elevated levels of DPP4 in fatty livers are the cause or consequence of the disease.
In order to find an answer to this question, scientists working with Schürmann and Baumeier compared two different groups of mice with each other. While one group of mice produced an increased amount of DPP4 in the liver due to a genetic modification, the control group showed low amounts of the enzyme. Both groups were given the same high-fat feed**** for approx. half a year. The animals that produced an increased amount of DPP4 in the liver gained about one-third more body fat than the control group and showed about twice as much liver fat. They also reacted less sensitive to the hormone insulin. Additional studies on a human liver cell line as well as on isolated liver cells of the mice also indicated that normal amounts of DPP4 (500ng/ml) are already sufficient to make the cells less sensitive to insulin regardless of their fat content. In addition, the scientists observed that human beings suffering from insulin resistance and non-alcoholic fatty liver disease have a greater amount of active DPP4 in their blood than healthy people.
"From other studies***** we know that epigenetic modifications of the DPP4 gene, which are associated with an increased production of the enzyme, have a negative impact on the liver metabolism already in young mice, long before fatty liver disease emerges," says Baumeier.
"It therefore seems reasonable to examine in further studies how and at what time DPP4 inhibitors can be used to prevent or to treat the development of a non-alcoholic fatty liver," added Schürmann, who heads the Department of Experimental Diabetology at the DIfE.
* DPP4 is the acronym for dipeptidyl peptidase 4. The enzyme cleaves, among others, some intestinal hormones (incretins) glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptides (GIP), which as a result lose their effectiveness. This leads to high blood glucose values; the function of the insulin-producing cells in the pancreas is also negatively influenced.
** DPP4 inhibitors are already used as a drug in the treatment of diabetes in order to prolong the effect of the two endogenous incretins GLP-1 and GIP. Their aim is to increase insulin secretion after food intake in people with type 2 diabetes.
*** Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in Europe and the United States and a frequent side effect of obesity and type 2 diabetes. Depending on the country, around 25 to 45 percent of adults are affected. Left untreated, a fatty liver can develop into liver cirrhosis with life-threatening consequences. Complete remission is possible, with weight reduction playing a major role (sources: the present study by Baumeier et al., 2017, and Deutsches Ärzteblatt, volume 111; issue 26; June 27, 2014).
**** Fat content of the feed contributes up to 45 percent of the energy supply.
***** Christian Baumeier, Sophie Saussenthaler, Anne Kammel, Markus Jähnert, Luisa Schlüter, Deike Hesse, Mickaël Canouil, Stephane Lobbens, Robert Caiazzo, Violeta Raverdy, François Pattou, Emma Nilsson, Jussi Pihlajamäki, Charlotte Ling, Philippe Froguel, Annette Schürmann and Robert W. Schwenk: Hepatic DPP4 DNA Methylation Associates With Fatty Liver. Diabetes 2017; 66 (1): 25-35.
تُستخدم مثبطات أنزيم (DPP4) المُنتج في الكبد في العديد من أدوية علاج مرض السكري من النمط الثاني بسبب تأثيرها الكبير على مقاومة الجسم للأنسولين، وفي هذه الدراسة اكتشف الباحثون أن مُثبطات هذا الأنزيم لها دور علاجي هام في علاج أمراض الكبد الدهنية الغير كحولية (NAFLD) والسمنة المفرطة.
اعتمد الباحثون خلال هذه الدراسة على نماذج فئران معدلة وراثياً لتُنتج كمية كبيرة من أنزيم (DPP4) في كبدها، ثم راقبوها بعد إعطائها نظام غذائي عالي الدهون، فلاحظوا أن هذه الفئران المعدلة وراثياً قد تأثرت لديها عملية الأيض بشكل سلبي مما ساعد على تخزين الدهون داخل جسمها وخاصة في منطقة الكبد لتُسبب أمراض الكبد الدهنية، كما أن حساسية هذه الفئران للأنسولين قد تضاءلت بشكل ملحوظ، وعند فحص مجموعة من مرضى السكري ومرضى (NAFLD) وجد الأطباء أن نسبة انزيم (DPP4) داخل دمائهم عالي مقارنة مع الأشخاص الأصحاء، وهذا يعطي مثبطات (DPP4) أهمية كبيرة في علاج (NAFLD) إضافة إلى علاج مرض السكري.
أُجري هذا البحث في : Deutsches Zentrum fuer Diabetesforschung DZD ونُشر في مجلة : Molecular Metabolism